JP2015519398A5 - - Google Patents

Download PDF

Info

Publication number
JP2015519398A5
JP2015519398A5 JP2015517316A JP2015517316A JP2015519398A5 JP 2015519398 A5 JP2015519398 A5 JP 2015519398A5 JP 2015517316 A JP2015517316 A JP 2015517316A JP 2015517316 A JP2015517316 A JP 2015517316A JP 2015519398 A5 JP2015519398 A5 JP 2015519398A5
Authority
JP
Japan
Prior art keywords
amount
weight
formulation
added
intermediate mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2015517316A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015519398A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/044617 external-priority patent/WO2013188217A1/en
Publication of JP2015519398A publication Critical patent/JP2015519398A/ja
Publication of JP2015519398A5 publication Critical patent/JP2015519398A5/ja
Ceased legal-status Critical Current

Links

JP2015517316A 2012-06-11 2013-06-06 治療用製剤および処置の方法 Ceased JP2015519398A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261658304P 2012-06-11 2012-06-11
US61/658,304 2012-06-11
PCT/US2013/044617 WO2013188217A1 (en) 2012-06-11 2013-06-06 Therapeutic formulation and methods of treatment

Publications (2)

Publication Number Publication Date
JP2015519398A JP2015519398A (ja) 2015-07-09
JP2015519398A5 true JP2015519398A5 (https=) 2016-07-21

Family

ID=49715792

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015517316A Ceased JP2015519398A (ja) 2012-06-11 2013-06-06 治療用製剤および処置の方法

Country Status (9)

Country Link
US (2) US9254287B2 (https=)
JP (1) JP2015519398A (https=)
KR (1) KR20150032552A (https=)
CN (1) CN104768533A (https=)
AU (1) AU2013274582A1 (https=)
HK (1) HK1212225A1 (https=)
SG (1) SG11201408230VA (https=)
TW (1) TW201410245A (https=)
WO (1) WO2013188217A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164419A1 (en) * 2014-04-22 2015-10-29 Acucela Inc. Pupillometric assessment of retinal pharmacodynamics and responses therefrom
CA2972575A1 (en) 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Rpe cell populations and methods of generating same
EP3697285A4 (en) * 2017-10-17 2021-06-30 Apeliotus Technologies, Inc. FUNCTIONAL BIOMARKERS FOR STATIN THERAPY IN AGE-RELATED MACULAR DEGENERATION (AMD)
WO2019130061A2 (en) * 2017-12-29 2019-07-04 Cell Cure Neurosciences Ltd. Retinal pigment epithelium cell compositions
CN112007031A (zh) * 2019-05-30 2020-12-01 杏国新药股份有限公司 眼用制剂
US12109211B2 (en) * 2021-12-29 2024-10-08 Endo Operations Limited Hydralazine compositions and methods

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4055645A (en) 1976-02-13 1977-10-25 Merck & Co., Inc. Novel anti-hypertensive compositions
FI873429A7 (fi) 1986-08-18 1988-02-19 Houston Biotechnology Incorporated Silmälääketieteelliset koostumukset hermodegeneraatioiden hoitoon.
US4865599A (en) 1986-08-18 1989-09-12 Houston Biotechnology, Inc. Ophthalmic compositions for treating nerve degeneration
EP0583821B1 (en) * 1987-01-23 2000-03-29 The General Hospital Corporation Hydralazine as topical treatment for glaucoma
US5500230A (en) 1987-01-23 1996-03-19 The General Hospital Corporation Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5252607A (en) 1992-01-24 1993-10-12 Texas A&M University System Treatment of low pressure glaucoma and ischemic retinal degeneration
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
TW264385B (https=) 1993-05-14 1995-12-01 Taiho Pharmaceutical Co Ltd
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US5596011A (en) 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
CA2252962A1 (en) 1996-04-26 1997-11-06 Fujisawa Pharmaceutical Co., Ltd. Peripheral circulation improvers for ophthalmic tissues containing dihydropyridines
WO1998010758A1 (en) 1996-09-13 1998-03-19 The Regents Of The University Of California Methods for treatment of retinal diseases
JP4828670B2 (ja) 1996-10-28 2011-11-30 千寿製薬株式会社 眼循環障害改善剤
WO1999044603A1 (en) 1998-03-06 1999-09-10 Sponsel William E Composition and method for treating macular disorders
US6028099A (en) 1998-03-13 2000-02-22 John Hopkins University, School Of Medicine Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization
EP1161686A2 (en) 1999-03-05 2001-12-12 University Of Iowa Research Foundation Diagnostics and therapeutics for drusen associated ocular disorders
IL137429A0 (en) 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
AU779991B2 (en) 1999-08-10 2005-02-24 Board Of Regents, The University Of Texas System Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight
US6692759B1 (en) 2000-06-28 2004-02-17 The Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
US20030171375A1 (en) 2002-02-13 2003-09-11 Brazzell Romulus Kimbro Method for treating ocular neovascular diseases
AU2003287250B9 (en) 2002-10-30 2010-01-28 Ptc Therapeutics, Inc. Identifying therapeutic compounds based on their physical-chemical properties
JP2004250347A (ja) 2003-02-18 2004-09-09 Ajinomoto Co Inc 網膜虚血に基づく疾患の治療および/又は予防剤
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
CA2576279A1 (en) 2004-11-08 2006-05-18 Nitromed, Inc. Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
JP2008531697A (ja) * 2005-02-28 2008-08-14 ニトロメッド インコーポレーティッド 酸化窒素増強基を含む心血管化合物、組成物および使用法
US8088773B2 (en) 2005-05-12 2012-01-03 The Texas A&M University System Therapeutic compositions and methods

Similar Documents

Publication Publication Date Title
JP2015519398A5 (https=)
JP2013500977A5 (https=)
HRP20221294T1 (hr) Neuroaktivni steroidi, njihovi pripravci i uporabe
JP2013542247A5 (https=)
JP2016027060A5 (https=)
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
JP2014505733A5 (https=)
HRP20171512T1 (hr) Derivati betulina
JP2015007136A5 (https=)
CA2920410C (en) Thienopiperidine derivative and use thereof
ITBO20110012A1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
RU2013150861A (ru) Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
SI2945620T1 (en) Nitroxyl donors with improved therapeutic index
JP2016503058A5 (https=)
NZ591205A (en) Pharmaceutical compositions comprising clevidipine and methods for producing low impurity concentrations of the same
BR112013022094A2 (pt) composições e métodos para o tratamento não cirúrgico da ptose
JP2017517553A5 (https=)
EP4218769A3 (en) Treatment of oculopharyngeal muscular dystrophy by intravenous administration of trehalose
EA201591653A1 (ru) Композиции для лечения глазных расстройств с применением дипиридамола
HRP20161389T1 (hr) Derivati pantotenata namijenjeni liječenju neuroloških poremećaja
MX2012007927A (es) Antagonistas de dp2 y usos del mismo.
EA201491870A1 (ru) Способ лечения гиперурикемии у больных подагрой с помощью галофената или галофеновой кислоты и противовоспалительного агента
BR112014004737A2 (pt) composto de composição de cloridrato de ambroxol e método de preparação do composto
EP2525819A4 (en) IMMUNOTHERAPY COMPOSITIONS AND TREATMENT PROCEDURES